A global view of hepatocellular carcinoma: trends, risk, prevention and management

JD Yang, P Hainaut, GJ Gores, A Amadou… - Nature reviews …, 2019 - nature.com
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …

[HTML][HTML] Predictors of early and late hepatocellular carcinoma recurrence

R Nevola, R Ruocco, L Criscuolo, A Villani… - World journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates
are constantly increasing. Despite the availability of potentially curative treatments (liver …

Breakthroughs in hepatocellular carcinoma therapies

AG Singal, M Kudo, J Bruix - Clinical Gastroenterology and Hepatology, 2023 - Elsevier
Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

G Cabibbo, C Celsa, V Calvaruso, S Petta… - Journal of …, 2019 - Elsevier
Background & Aims The effectiveness of direct-acting antivirals (DAAs) against hepatitis C
virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has …

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

V Sapena, M Enea, F Torres, C Celsa, J Rios… - Gut, 2022 - gut.bmj.com
Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma

AG Singal, NE Rich, N Mehta, AD Branch, A Pillai… - Gastroenterology, 2019 - Elsevier
Background & Aims There is controversy regarding the benefits of direct-acting antiviral
(DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of …

[HTML][HTML] Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma

C Akateh, SM Black, L Conteh, ED Miller… - World journal of …, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a
major cause of cancer-related mortality for which liver resection is an important curative …

Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation

F Bonifazi, F Barbato, F Ravaioli, M Sessa… - Frontiers in …, 2020 - frontiersin.org
Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is a rare
complication characterized by hepatomegaly, right-upper quadrant pain, jaundice, and …

Incidence of liver-and non-liver-related outcomes in patients with HCV-cirrhosis after SVR

R D'Ambrosio, E Degasperi, MP Anolli, I Fanetti… - Journal of …, 2022 - Elsevier
Background & Aims As the long-term benefits of a sustained virological response (SVR) in
HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we …

[HTML][HTML] Viral hepatitis: Milestones, unresolved issues, and future goals

P Torre, A Aglitti, M Masarone… - World journal of …, 2021 - ncbi.nlm.nih.gov
In this review the current overall knowledge on hepatitis A, B, C, D, and E will be discussed.
These diseases are all characterized by liver inflammation but have significant differences in …